You have seen the billboards. Serena Williams. Charles Barkley. GLP-1 medications are everywhere, and so are their costs.
For employers, this is not just a cultural moment. It is a financial one that is showing up directly in your health plan, and there is a good chance your benefits advisor has not had a serious conversation with you about it yet.
What is actually happening
Between 2022 and 2024, allowed costs for employers covering GLP-1s for weight management rose nearly 840%, from $2.41 to $22.59 per member per month. That number is only going in one direction. A recent KFF survey found that 12% of American adults are already taking these medications. Oral versions are now available at self-pay prices starting around $149 per month, which means the barrier to entry just got lower, and more of your employees will be starting therapy.
This is not a trend to monitor. It is a cost driver that is already affecting plans right now.
Why this is harder to manage than other expensive drugs
High-cost medications like cancer treatment, gene therapy, and transplants are episodic. They generate large individual claims, they hit stop-loss deductibles, and carriers know how to price for that kind of exposure.
GLP-1s are different. They are maintenance drugs. Patients take them indefinitely to stay effective. Individual prescriptions often sit below specific stop-loss attachment points, so they do not trigger the usual alerts. But sustained use across a growing portion of your covered population compounds into aggregate pressure that traditional underwriting models were not built to handle.
If 20% of a 300-person group starts GLP-1 therapy, you could be looking at $600,000 in additional annual pharmacy spend. For many employers, that is enough to breach an aggregate stop-loss threshold on pharmacy alone.
The part many advisors are missing
Pharmacy benefits and stop-loss strategy have traditionally been handled as two separate conversations. Separate teams, separate timelines, separate renewals. That approach made some sense in the past. It does not make sense anymore.
When your plan makes a decision about GLP-1 coverage, whether to add it, restrict it, or drop it entirely, that decision has direct consequences for your stop-loss pricing, your aggregate attachment points, and your claims volatility going forward. Those dots need to be connected before a coverage decision is made, not after the renewal comes in.
If your advisor is not bringing your pharmacy utilization data into the stop-loss conversation in real time, you are likely heading into your next renewal with less information than you should have.
Cutting coverage is not always the answer
Some employers are reacting to rising GLP-1 costs by removing coverage altogether. That is understandable, but it is worth thinking through carefully. Obesity and its related conditions, including diabetes, cardiovascular disease, and joint issues, do not disappear when you remove the drug coverage. Those costs tend to show up later as higher medical claims. The risk moves; it does not go away.
The better path is a proactive strategy around your Rx formulary and how you are procuring these medications. There are ways to access GLP-1s and other specialty drugs for 25-50% less than traditional channels. If your advisor has not walked you through those options, it is a fair question to ask why.
What you should be asking right now
- Has your advisor reviewed your pharmacy utilization data alongside your stop-loss structure?
- Do you have a strategy for managing GLP-1 costs that goes beyond adding or removing coverage?
- Are you exploring alternative procurement options for specialty medications?
If the answers are unclear, that is worth addressing before your next renewal, not during it.
DM me for more information.